General MedicationsORALGeneric
NILANDRON
NILUTAMIDE
Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview NILANDRON is listed in Drugs@FDA under application 020169 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient NILUTAMIDE Form and strength TABLET;ORAL - 50MG Sponsor ADVANZ PHARMA Submission history Latest submission status date: 2017-05-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview NILANDRON is listed in Drugs@FDA under application 020169 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NILUTAMIDE Form and strength TABLET;ORAL - 50MG Sponsor ADVANZ PHARMA Submission history Latest submission status date: 2017-05-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.